Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Features

Valvular Heart Disease Has a Diversity Problem

Yael L. Maxwell

July 12, 2024

News Daily News

Undiagnosed Valvular Heart Disease Prevalent in Older Adults

Yael L. Maxwell

June 27, 2024

Presentation NY Valves 2024

The Landscape of Novel Methods to Screen for VHD

Presenter: Sreekanth Vemulapalli

June 06, 2024

Presentation NY Valves 2024

Using Real-world Data in VHD: Sources, Successes, and Failures

Presenter: Sreekanth Vemulapalli

June 06, 2024

News Daily News

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

Michael O'Riordan

March 15, 2024

Presentation TVT 2022

From National Registries to Pragmatic Clinical Trials, From Patient-Reported Outcomes to Shared Decision-making: Not One Size Fits All!

Presenter: Sreekanth Vemulapalli

June 08, 2022

News Daily News

US Aortic Valve Trends in Older Patients Hint at Better Outcomes, Access

L.A. McKeown

November 23, 2021

News Daily News

Most US Patients Have TAVR Options Nearby, but Proximity Isn’t Everything

Todd Neale

June 12, 2020

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Daily News

Fragmented TAVR Care Common, Linked to Death and Readmission

L.A. McKeown

July 08, 2019

News Daily News

Volume Still an Important Surrogate for TAVR Quality, New Data Suggest

Todd Neale

April 03, 2019

News Daily News

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

L.A. McKeown

March 13, 2019

Advertisement

Valvular Heart Disease Has a Diversity Problem

Undiagnosed Valvular Heart Disease Prevalent in Older Adults

The Landscape of Novel Methods to Screen for VHD

Using Real-world Data in VHD: Sources, Successes, and Failures

M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes

From National Registries to Pragmatic Clinical Trials, From Patient-Reported Outcomes to Shared Decision-making: Not One Size Fits All!

US Aortic Valve Trends in Older Patients Hint at Better Outcomes, Access

Most US Patients Have TAVR Options Nearby, but Proximity Isn’t Everything

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Fragmented TAVR Care Common, Linked to Death and Readmission

Volume Still an Important Surrogate for TAVR Quality, New Data Suggest

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content